Precision Biosciences Inc. DTIL
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2019 · data as of November 13, 2026
Precision Biosciences Inc. (DTIL) is a healthcare company listed in the US with a market value of about $288M. In the twelve months to September 30, 2026 it had revenue of $45M and net income of -$39M, a net margin of -85.6%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 7% a year, a 5-year average ROIC of -61%.
About Precision Biosciences
Precision Biosciences is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2019. Revenue went from $11M in 2018 to $34M in 2025, growth of about 17.8% a year. It was profitable in 1 of the last 8 years in our data. Its share count rose by 338% over three years (dilution for shareholders). It spends 158% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $45M | $34M | $69M | $49M | $25M | $116M | $24M | $1.1B | $11M |
| Net income | -$39M | -$46M | $7M | -$61M | -$112M | -$31M | -$109M | -$93M | -$46M |
| Free cash flow | -$52M | -$66M | -$59M | -$86M | -$49M | -$16M | -$92M | -$96M | -$66M |
| EPS (diluted) | $-1.00 | $-1.19 | $0.35 | $-5.32 | $-12.70 | $-5.20 | $-20.90 | $-22.10 | $-29.20 |
| Net margin | -85.6% | -133.4% | 10.4% | -125.8% | -444.8% | -26.5% | -448.9% | -8.7% | -423.0% |
| ROIC | — | -52.9% | -40.8% | -124.7% | -56.3% | -31.0% | -157.9% | -49.8% | -94.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $29.40, 289% above the current price; targets range from $18.00 to $60.00; the consensus rating is “Strong buy”; expected EPS is $-2.85 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Precision Biosciences pay a dividend?
Not currently.
Is Precision Biosciences a good stock to buy?
We do not give buy or sell advice. Precision Biosciences scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.